Table 1.
Biometric data of all volunteers included in this study.
| Total number of relapse | Duration of IFN-β1b treatment in years | ||||||
|---|---|---|---|---|---|---|---|
| n | m/f | Age in years | Duration of MS in years | Before treatment | Under treatment | ||
| Healthy controls | 20 | 3/17 | 34·1 ± 11·3 | ||||
| MS patients without DMT | 18 | 6/12 | 35·2 ± 11·3 | 6·5 ± 9·4 | 2·2 ± 2·3 | ||
| IFN-β1b-treated MS patients | 10 | 3/7 | 41·4 ± 9·5 | 8·9 ± 8·4 | 3·1 ± 3·0 | 1·5 ± 1·4 | 4·5 ± 5·2 |
m = male; f = female. Mean values ± SD are shown.